Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin
- 1 September 2002
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (6) , 359-366
- https://doi.org/10.1038/sj.bmt.1703667
Abstract
Twenty-one paediatric patients (11 males and 10 females) received a CD34-selected partially matched related donor transplant for malignant (16 cases) and non-malignant conditions (five cases). The average cell dose was 11.13 x 10(6)/kg. Fifteen of 16 patients with malignant conditions and one with non-malignant disease received total body irradiation plus cyclophosphamide. Three of 5 patients with non-malignant conditions and one with leukaemia, received busulphan plus cyclophosphamide. One patient with Fanconi anaemia received 100 mg/kg of cyclophosphamide. Fludarabine (25 mg/m(2)/day for 5 days) was administered prior to all these regimens. Additionally, anti-lymphocyte gamma-globulin (12.5 mg/kg/day) was administered from day -2 to day +2. Three (15%) patients failed to achieve complete chimaerism (CC). These patients received a second cell infusion. Two of them achieved CC. In the third patient, the percentage of donor cells was increased. The likelihood for engraftment was not related to the cell dose received. Acute graft-versus-host disease (GVHD) occurred in nine patients but only one developed GVHD >grade II. Eight patients developed active viral infections, which resolved after treatment. Patients receiving cell doses higher than our average had a significantly faster CD3 and CD4 cell recovery and experienced a lower incidence of viral infections. After 480 +/- 255 days of median follow-up, 16/21 patients are alive and well and have CC. Three patients died of leukaemic relapse and a fourth from progression of his disease (adreno-leuko-dystrophy). We conclude that partially matched related donors are a feasible source of haemopoietic progenitor cells for transplantation for patients without matched familial or unrelated donors.Keywords
This publication has 18 references indexed in Scilit:
- Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplantsBone Marrow Transplantation, 2000
- Fludarabine-based Protocol for Haploidentical Peripheral Blood Stem Cell Transplantation in Hurler SyndromeJournal of Pediatric Hematology/Oncology, 2000
- CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation.Bone Marrow Transplantation, 2000
- Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftmentLeukemia, 1999
- Transplantation of Megadoses of Purified Haploidentical Stem CellsAnnals of the New York Academy of Sciences, 1999
- Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesBlood, 1998
- Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1997
- Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow TransplantBlood, 1997
- Use of stem cells from mismatched related donorsCurrent Opinion in Hematology, 1997
- Mismatched bone marrow transplantationCurrent Opinion in Oncology, 1995